Xingang Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xingang Cui has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Qing Yang
Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China
2 shared publicationsQiwei Yang
Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China; Department of Urology, The Third Affiliated Hospital of Second Military Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, 201805, People's Republic of China; Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, People's Republic of China
2 shared publicationsXiuwu Pan
Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, People's Republic of China
2 shared publications- Ye Wang
Department of Urology, Chinese PLA General Hospital, Beijing, China
2 shared publications - Yinghao Sun
Department of Urology, Shanghai Changhai Hospital, Shanghai, China
2 shared publications Chen-Xia Sun
The Reproductive Center, Institute for Nutritional Sciences, Shanghai Institute for Biological Science, Chinese Academy of Science, Shanghai, People's Republic of China
1 shared publication
Latest Publications
- 1 November 2017
- Published by Elsevier in Biomaterials
- Vol. 146, 72-85
Cuprous oxide nanoparticles trigger ER stress-induced apoptosis by regulating copper trafficking and overcoming resistance to sunitinib therapy in renal cancer
- 1 November 2017
- Published by Elsevier in Biomaterials
- Vol. 146, 72-85
Cuprous oxide nanoparticles trigger ER stress-induced apoptosis by regulating copper trafficking and overcoming resistance to sunitinib therapy in renal cancer
- Open Access
- 8 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (45) , 78989-79002
Frizzled 8 promotes the cell proliferation and metastasis of renal cell carcinoma
Frizzled 8 promotes the cell proliferation and metastasis of renal cell carcinoma Frizzled 8 promotes the cell proliferation and metastasis of renal cell carcinoma
- 8 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (45) , 78989-79002
Open AccessFrizzled 8 promotes the cell proliferation and metastasis of renal cell carcinoma
Frizzled 8 promotes the cell proliferation and metastasis of renal cell carcinoma Frizzled 8 promotes the cell proliferation and metastasis of renal cell carcinoma
- Open Access
- 1 March 2017
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 12, 2569-2579
Cuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway
Disordered copper metabolism plays a critical role in the development of various cancers. As a nanomedicine containing copper, cuprous oxide nanoparticles (CONPs) exert ideal antitumor pharmacological effects in vitro and in vivo. Prostate cancer is a frequently diagnosed male malignancy prone to relapse, and castration resistance is the main reason for endocrine therapy failure. However, whether CONPs have the potential to treat castration-resistant prostate cancer is still unknown. Here, using the castration-resistant PC-3 human prostate cancer cell line as a model, we report that CONPs can selectively induce apoptosis and inhibit the proliferation of cancer cells in vitro and in vivo without affecting normal prostate epithelial cells. CONPs can also attenuate the stemness of cancer cells and inhibit the Wnt signaling pathway, both of which highlight the great potential of CONPs as a new clinical castration-resistant prostate cancer therapy.
- 1 March 2017
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 12, 2569-2579
Open AccessCuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway
Disordered copper metabolism plays a critical role in the development of various cancers. As a nanomedicine containing copper, cuprous oxide nanoparticles (CONPs) exert ideal antitumor pharmacological effects in vitro and in vivo. Prostate cancer is a frequently diagnosed male malignancy prone to relapse, and castration resistance is the main reason for endocrine therapy failure. However, whether CONPs have the potential to treat castration-resistant prostate cancer is still unknown. Here, using the castration-resistant PC-3 human prostate cancer cell line as a model, we report that CONPs can selectively induce apoptosis and inhibit the proliferation of cancer cells in vitro and in vivo without affecting normal prostate epithelial cells. CONPs can also attenuate the stemness of cancer cells and inhibit the Wnt signaling pathway, both of which highlight the great potential of CONPs as a new clinical castration-resistant prostate cancer therapy.